|Bid||2.2500 x 0|
|Ask||1.9450 x 0|
|Day's Range||1.9400 - 2.1800|
|52 Week Range||1.0150 - 2.4700|
|Beta (3Y Monthly)||2.02|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If you're interested in Mesoblast Limited (ASX:MSB), then you might want to consider its beta (a measure of share...
Statistically speaking, long term investing is a profitable endeavour. But unfortunately, some companies simply don't...
Mesoblast Limited (NASDAQ: MESO ) product rexlemestrocel-L has received Orphan Drug Destination from the U.S. Food and Drug Administration for prevention of gastrointestinal bleeding in patients with left ...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Silviu Itescu became the CEO of Mesoblast Limited (ASX:MSB) in 2011. First, this article will compare CEO compensa...
Mesoblast Limited's (ASX:MSB): Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. With the latest financial year loss of -US$35.3m and a trailing-twelve month of -US$86.1m, the AU$624mRead More...
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.